The Arras plant officially becomes a pharmaceutical site

LFB’s future plant in Arras reaches a crucial milestone: the official authorisation to open a pharmaceutical site is issued by the ANSM, the French National Agency for Medicines and Health Products Safety.
This plant will ultimately triple LFB’s fractionation capacity.
It is scheduled to start operations by the end of 2024 and will strengthen France’s health sovereignty in plasma-derived medicinal products.

All the teams involved in this strategic project deserve our most heartfelt congratulations.